IL-18, a biomarker of human ovarian carcinoma [24], is known to enhance immunosuppressive responses by impairing the antitumor function of natural killer (NK) cells [25] or promoting the differentiation of monocytes into MDSCs [26], indicating that IL-18 is the key mediator of the interaction between tumor and tumor promoting immune cells in the microenvironment. This evidence concerns the gene IL18 and ovarian carcinoma.